The Use of Beta-Blockers in Advanced Cirrhosis—Where Do We Stand?

被引：0
作者：
Abraldes J.G. [1 ]
Tandon P. [1 ]
机构：
[1] Cirrhosis Care Clinic (CCC), Liver Unit, Division of Gastroenterology, University of Alberta, Zeidler Ledcor Building, Edmonton, T6G-2X8, AB
来源：
Current Hepatology Reports | 2015年 / 14卷 / 1期
关键词：
Carvedilol; Nadolol; Portal hypertension; Propranolol; Variceal bleeding;
D O I：
10.1007/s11901-015-0256-8
中图分类号：
学科分类号：
摘要：
Non-selective beta-blockers (NSBBs) have been used for over 30 years in the treatment of portal hypertension in patients with cirrhosis. They have proven efficacy in preventing first variceal bleeding and rebleeding and in reducing mortality. NSBBs might additionally reduce the risk of infections in cirrhosis. Recent data suggest that patients with refractory ascites or that have experienced a spontaneous bacterial peritonitis might have an increased mortality if they are treated with NSBBs. The lack of randomized trials, and the conflicting results from observational studies, makes it difficult to reach a definitive conclusion. In this article, we review the current evidence on the benefits and harms of NSBBs in cirrhosis and provide recommendations for their use in special populations. © 2015, Springer Science+Business Media New York.
引用
收藏
页码：46 / 52
页数：6
相关论文
共 45 条
  • [1] Ripoll C., Groszmann R., Garcia-Tsao G., Grace N., Burroughs A., Planas R., Et al., Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis, Gastroenterology, 133, pp. 481-488, (2007)
  • [2] Bosch J., Abraldes J.G., Berzigotti A., Garcia-Pagan J.C., The clinical use of HVPG measurements in chronic liver disease, Nat Rev Gastroenterol Hepatol, 6, pp. 573-582, (2009)
  • [3] Garcia-Tsao G., Groszmann R.J., Fisher R.L., Conn H.O., Atterbury C.E., Glickman M., Portal pressure, presence of gastroesophageal varices and variceal bleeding, Hepatology, 5, pp. 419-424, (1985)
  • [4] Abraldes J.G., Tarantino I., Turnes J., Garcia-Pagan J.C., Rodes J., Bosch J., Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis, Hepatology, 37, pp. 902-908, (2003)
  • [5] Vorobioff J., Groszmann R.J., Picabea E., Gamen M., Villavicencio R., Bordato J., Et al., Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study, Gastroenterology, 111, pp. 701-709, (1996)
  • [6] Groszmann R.J., Abraldes J.G., Portal hypertension: from bedside to bench, J Clin Gastroenterol, 39, pp. S125-S130, (2005)
  • [7] Bosch J., Masti R., Kravetz D., Bruix J., Gaya J., Rigau J., Et al., Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis, Hepatology, 4, pp. 1200-1205, (1984)
  • [8] Feu F., Bordas J.M., Luca A., Garcia-Pagan J.C., Escorsell A., Bosch J., Et al., Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis, Hepatology, 18, pp. 1082-1089, (1993)
  • [9] Escorsell A., Bordas J.M., Feu F., Garcia-Pagan J.C., Gines A., Bosch J., Et al., Endoscopic assessment of variceal volume and wall tension in cirrhotic patients: effects of pharmacological therapy, Gastroenterology, 113, pp. 1640-1646, (1997)
  • [10] Escorsell A., Bordas J.M., Castaneda B., Llach J., Garcia-Pagan J.C., Rodes J., Et al., Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension, Hepatology, 31, pp. 1061-1067, (2000)
12345